We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Illumina to Appeal FTC’s Order to Divest Liquid Biopsy Maker Grail
Illumina to Appeal FTC’s Order to Divest Liquid Biopsy Maker Grail
Illumina said it will appeal a Federal Trade Commission (FTC) order to divest itself of Grail — developer of the Galleri early detection liquid biopsy test to screen for multiple types of cancer.